New insights into stage and prognosis in small cell lung cancer: an analysis of 968 cases

被引:30
作者
Dayen, Charles [1 ]
Debieuvre, Didier [2 ]
Molinier, Olivier [3 ]
Raffy, Olivier [4 ]
Paganin, Fabrice [5 ]
Virally, Jerome [6 ]
Larive, Sebastien [7 ]
Desurmont-Salasc, Beatrice [8 ]
Perrichon, Marielle [9 ]
Martin, Francis [10 ]
Grivaux, Michel [11 ]
机构
[1] Hop St Quentin, Resp Med Dept, 1 Ave Michel Hosp, F-02321 St Quentin En Yvelines, France
[2] Hop Emile Muller, Grp Hosp Reg Mulhouse Sud Alsace, Resp Med Dept, Mulhouse, France
[3] Hop Mans, Resp Med Dept, Le Mans, France
[4] Hop Louis Pasteur, Resp Med Dept, Le Coudray, France
[5] Hop Sud La Reunion, Resp Med Dept, St Pierre, Reunion, France
[6] Ctr Hosp Intercommunal Robert Ballanger, Resp Med Dept, Aulnay Sous Bois, France
[7] Hop Les Chanaux, Resp Med Dept, Macon, France
[8] Ctr Hosp Intercommunal Frejus St Raphael, Resp Med Dept, St Raphael, France
[9] Hop Fleyriat, Resp Med Dept, Bourg En Bresse, France
[10] Ctr Hosp Intercommunal Compiegne Noyon, Pneumol & Sleep Disorders Dept, Compiegne, France
[11] Hop Meaux, Resp Med Dept, Meaux, France
关键词
Epidemiology; France; hospitals; general; mortality; small cell lung cancer (SCLC); stage; CHEMOTHERAPY; SURGERY; SURVIVAL; FRANCE;
D O I
10.21037/jtd.2017.11.52
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background: The French College of General Hospital Respiratory Physicians conducted two studies that consecutively included all patients followed in participating general hospitals for primary small cell (SCLC) or non-small cell (NSCLC) lung cancer diagnosed in 2000 and 2010. These studies allow descriptive statistics and outcome assessment for SCLC and NSCLC separately and comparison over a 10-year period. Methods: A standardised form was completed for each patient at inclusion. Then, vital status was collected. Results: In 2000 and 2010, 948 (15.5% female) and 968 (23.3%) SCLC patients, mainly heavy active-or former-smoker seniors, participated in these studies. One-year survival rate was 35.8% for SCLC vs. 44.8% for NSCLC in 2010 and 33.1% for SCLC in 2000. In 2010, in reference to stage 0-IIB (4.1% of SCLCs), the hazard ratio was 0.92 [95% confidence interval (CI): 0.6-1.5; P=0.76], 1.8 (95% CI: 1.1-2.8; P=0.019), and 3.4 (95% CI: 2.2-5.3; P<0.001) for stage IIIA (10.2%), IIIB (14.5%), and IV (71.2%). Positron emission tomography (PET)-scan use, which has increased in 10 years, was frequent in patients with limited disease. Conclusions: One-year survival in SCLC patients was poor in 2010 and dependent of SCLC stage. TNM classification reintroduction and new diagnostic techniques (e.g., PET-scan) should allow lung oncologists to tailor treatment based on disease stage at diagnosis.
引用
收藏
页码:5101 / 5111
页数:11
相关论文
共 31 条
[1]   DETERMINANTS OF IMPROVED OUTCOME IN SMALL-CELL LUNG-CANCER - AN ANALYSIS OF THE 2,580-PATIENT SOUTHWEST ONCOLOGY GROUP DATA-BASE [J].
ALBAIN, KS ;
CROWLEY, JJ ;
LEBLANC, M ;
LIVINGSTON, RB .
JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (09) :1563-1574
[2]  
Bischof M, 2007, STRAHLENTHER ONKOL, V183, P679, DOI 10.1007/s00066-007-1740-z
[3]  
Blanchon F, 2002, REV MAL RESPIR, V19, P727
[4]   4-year mortality in patients with non-small-cell lung cancer: Development and validation of a prognostic index [J].
Blanchon, Francois ;
Grivaux, Michel ;
Asselain, Bernard ;
Lebas, Francois-Xavier ;
Orlando, Jean-Pierre ;
Piquet, Jacques ;
Zureik, Mahmoud .
LANCET ONCOLOGY, 2006, 7 (10) :829-836
[5]   Impact of [18F]FDG-PET on the primary staging of small-cell lung cancer [J].
Brink, I ;
Schumacher, T ;
Mix, M ;
Ruhland, S ;
Stoelben, E ;
Digel, W ;
Henke, M ;
Ghanem, N ;
Moser, E ;
Nitzsche, EU .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2004, 31 (12) :1614-1620
[6]   Surgical resection of limited disease small cell lung cancer in the new era of platinum chemotherapy: Its time has come [J].
Brock, MV ;
Hooker, CM ;
Syphard, JE ;
Westra, W ;
Xu, L ;
Alberg, AJ ;
Mason, D ;
Baylin, SB ;
Herman, JG ;
Yung, RC ;
Brahmer, J ;
Rudin, CM ;
Ettinger, DS ;
Yang, SC .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2005, 129 (01) :64-72
[7]   Whole body FDG-PET for the evaluation and staging of small cell lung cancer: a preliminary study [J].
Chin, R ;
McCain, TW ;
Miller, AA ;
Dunagan, DP ;
Acostamadiedo, J ;
Case, LD ;
Harkness, BA ;
Adler, LP ;
Haponik, EF .
LUNG CANCER, 2002, 37 (01) :1-6
[8]   Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer [J].
De Ruysscher, D ;
Pijls-Johannesma, M ;
Bentzen, SM ;
Minken, A ;
Wanders, R ;
Lutgens, L ;
Hochstenbag, M ;
Boersma, L ;
Wouters, B ;
Lammering, G ;
Vansteenkiste, J ;
Lambin, P .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (07) :1057-1063
[9]   Ten-year evolution in non-small-cell lung cancer according to sex. Results of the KBP-2010-CPHG study by the College of General Hospital Respiratory Physicians [J].
Debieuvre, D. ;
Locher, C. ;
Neidhardt, A. -C. ;
Goupil, F. ;
Lemaire, B. ;
Blanchet-Legens, A. -S. ;
Renault, D. ;
Tavernier, J. -Y. ;
Tagu, P. ;
Mahmoud, H. ;
Figueredo, M. ;
Grivaux, M. .
REVUE DES MALADIES RESPIRATOIRES, 2014, 31 (09) :805-816
[10]   The new face of non-small-cell lung cancer in men: Results of two French prospective epidemiological studies conducted 10 years apart [J].
Debieuvre, Didier ;
Oster, Jean-Philippe ;
Riou, Robert ;
Berruchon, Jacques ;
Levy, Antoine ;
Mathieu, Jean-Pierre ;
Dumont, Patrick ;
Leroy-Terquem, Etienne ;
Tizon-Couetil, Veronique ;
Martin, Francis ;
Grivaux, Michel .
LUNG CANCER, 2016, 91 :1-6